Monsanto Fined $2.5 Million For EPA Violations

Monsanto. has agreed to pay a $2.5 million penalty for misbranding biotech cotton seed products in what regulators called the largest civil administrative penalty settlement ever received for violating U.S. insecticide law.

The U.S. Environmental Protection Agency said St. Louis-based Monsanto, the world's largest seed company, violated the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) when it sold and distributed cotton seed products containing genetically engineered pesticides in a manner that violated restrictions Monsanto had told the EPA it would adhere to.

"This agreement shows that when a company violates the law by distributing misbranded pesticides, EPA will take action," said Cynthia Giles, assistant administrator for EPA's Office of Enforcement and Compliance Assurance in a statement.

The EPA said it found that between 2002 and 2007, Monsanto distributed or sold Bollgard and Bollgard II cotton seed products contain genetically engineered pesticides more than 1,700 times nationwide without the planting restrictions that EPA required to protect against pest resistance.

"People who manufacture and distribute pesticide products must follow the federal registration requirements," said Steve Owens, assistant administrator for EPA's Office of Chemical Safety and Pollution Prevention. "These requirements are critical to preventing the development and spread of insect resistance." EPA officials said Monsanto has since corrected the misbranding problems.

Monsanto officials were not immediately available for comment.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.